IND submission is one of the most visible milestones in early drug development. But treating the IND as the starting point for clinical strategy can be a costly mistake. By the time an asset is ready for IND submission, many decisions that shape its clinical path should already be taking form.
From Regulatory Milestone to Development Roadmap
A well-prepared IND is essential, but it is not sufficient on its own to ensure a successful clinical development program. Sponsors also need to understand how early clinical evidence will inform the decisions that follow—from dose and patient selection to subsequent study design and regulatory strategy.
FDA guidance on pre-IND meetings highlights the value of early interaction between sponsors and regulators. These discussions can help clarify the design of first-in-human studies, identify potential regulatory issues, and support a more complete IND submission. Just as importantly, they give sponsors an opportunity to align the development program with regulatory expectations before substantial resources are committed. [1]
Designing Studies Around Future Decisions
Clinical trials do more than generate data; they create the evidence used to determine what should happen next. A Phase 1 study, for example, may provide information on safety, tolerability, pharmacokinetics, and dosing. Those findings can shape Phase 2 design and influence the evidence strategy for later-stage development.
The International Council for Harmonisation’s E8(R1) guideline emphasizes quality by design in clinical research: identifying the factors that are critical to generating reliable and meaningful evidence and addressing them prospectively in study planning. [2]
For sponsors, that means asking strategic questions early:
- What does this study need to tell us?
- Which patient population will provide the most meaningful evidence?
- What endpoints and biomarkers will inform the next development decision?
- What evidence may regulators need as the program progresses?
- What uncertainties should this study reduce while maintaining appropriate participant protection?
Connecting Clinical Strategy With Business Decisions
Clinical decisions are also business decisions. Study design influences development timelines, capital requirements, operational complexity, and the evidence available to investors, partners, and potential acquirers. A technically sound program that does not anticipate these downstream decisions may still require costly changes later.
When clinical, regulatory, medical, and commercial considerations are addressed early, sponsors can make more informed choices about development priorities, resource allocation, and risk. Early planning does not eliminate uncertainty, but it can reduce avoidable rework and help teams respond more effectively as new evidence emerges.
Building a More Intentional Path to Development
Developing a clinical strategy before IND submission does not mean finalizing every future trial in advance. It means establishing a clear development direction while preserving the flexibility to adapt as evidence becomes available.
The IND is a significant milestone, but it is only one stage in a much longer development process. By considering the broader clinical pathway early, sponsors can design programs that connect scientific objectives, regulatory requirements, and the evidence needed to move a promising therapy forward.
The question isn’t simply whether an asset is ready for IND submission. It’s whether the clinical program is designed to generate the evidence needed for the decisions that follow.
References
[1] U.S. Food and Drug Administration. Guidance and resources related to pre-IND meetings and early regulatory interaction.
[2] International Council for Harmonisation. E8(R1): General Considerations for Clinical Studies.
